It is the end of 2018, so it is high time to summarize our company’s success over the past year. Natalia Nayanova, Accell’s Founder and Clinical Operations Director, shares her perspective on the company’s overall progress:

“I don’t wish to brag, but Accell once again became a top-recruiter in a multinational oncology study. This is a fact, so I think we can safely say that we have the bragging rights when we officially closed the patient enrolment on October 31, 2018. With just 6 Eastern European and CIS countries, Accell recruited 34% of all patients in the global trial that took place in 20+ countries.”

It is important to mention, that Russia alone enrolled almost 20% of all patients in the study worldwide. This fact clearly indicates that the clinical trials landscape is by no means affected by the currently tense political climate. Clinical operations run smoothly, and clinical trials outcomes are as predictable as ever including regulatory timelines and patient recruitment. Quality of data is not affected. Of course, because of swift patient recruitment dynamics, we normally get audited. This year Accell’s sites had a number of both Sponsor-initiated and independent audits; all of them we passed with flying colors and received tremendous words of appreciation for the work the company has done.

Aside from our prominent results in the leading oncology projects, Accell’s clinical team launched in Eastern Europe and Russia a multinational cardiovascular disease trial with a total number of 12,000 patients participating worldwide and started active enrolment. Our team kept on working with other current projects and built a strong basis for next year’s studies in CNS, allergy, and ophthalmology.

2018 was a productive year during which Accell clearly demonstrated its top position on the Eastern European market of clinical research. Becoming a winner of the Healthcare & Pharmaceutical Awards 2018 for ‘The Best Clinical Trial Management Firm – Eastern Europe’ attests to Accell’s commitment and strong business and ethical principles. Besides, in 2018 we finalized the launch of ACCELL ONCOLOGY division, became a member of a Clinical & Contract Research (CCRA) Association, attended and exhibited at a number of key industry events (including ASCO and ESMO), established new partnerships, and opened up new horizons.

I am optimistic about the upcoming year of 2019 with even more studies and projects on the way. I cordially thank all our partners and clients who we have had the privilege to work with during the year, and I look forward to an even closer collaboration to fulfill the mutual benefit and prosperity for us all.

Merry Christmas and Happy New Year 2019!”